Empowered Patient Podcast

Fred Colen, Chief Executive Officer, Neovasc sheds light on the four classes of angina and how the quality of life deteriorates for patients suffering from symptoms. Looking for the fundamental reason for the chronic condition of refractory angina has led Neovasc to address the small blood vessels inside the myocardium, the muscle of the heart. With their interventional cardiology procedure, the implanted device increases the pressure inside these small arteries and improves all symptoms.

@neovasc #RefractoryAngina #angina #heartdisease

Neovasc.com

Listen to the podcast here

Fred Colen, Chief Executive Officer, Neovasc sheds light on the four classes of angina and how the quality of life deteriorates for patients suffering from symptoms. Looking for the fundamental reason for the chronic condition of refractory angina has led Neovasc to address the small blood vessels inside the myocardium, the muscle of the heart. With their interventional cardiology procedure, the implanted device increases the pressure inside these small arteries and improves all symptoms.

@neovasc #RefractoryAngina #angina #heartdisease

Neovasc.com

Download the transcript here

Brian Culley, CEO, Lineage Cell Therapeutics talks about the risk we all face from developing age-related macular degeneration - both wet AMD and dry AMD. While there are treatments for wet AMD, currently there is no interventional approved treatment for dry AMD. Lineage is developing a ground-breaking treatment for dry AMD that includes injecting new retina cells into the back of the eye which then multiply and repair and even reverse the damage to the eye.

@LineageCell #AMD #WetAMD #DryAMD #eyehealth #celltherapy

LineageCell.com

Listen to the podcast here.

Brian Culley, CEO, Lineage Cell Therapeutics talks about the risk we all face from developing age-related macular degeneration - both wet AMD and dry AMD. While there are treatments for wet AMD, currently there is no interventional approved treatment for dry AMD. Lineage is developing a ground-breaking treatment for dry AMD that includes injecting new retina cells into the back of the eye which then multiply and repair and even reverse the damage to the eye.

@LineageCell #AMD #WetAMD #DryAMD #eyehealth #celltherapy

LineageCell.com

Download the transcript here.

Omri Shor, CEO and co-founder, Medisafe talks about the different aspects of medication adherence and challenges faced by patients trying to maintain their drug therapy schedules. With an eye towards personalized medicine, Medisafe strives to build bridges and integrate healthcare services for patients to allow them to better track and manage their health particularly In the age of COVID-19 when patients as well as caregivers are facing new challenges. While being HIPAA and GDPR compliant, Medisafe can also provide valuable information to drug manufacturers and doctors about common barriers to drug adherence.

@medisafeapp #precisionsmedicine #medicationadherence #COVID19

Medisafe.com

Listen to the podcast here.

Omri Shor, CEO and co-founder, Medisafe talks about the different aspects of medication adherence and challenges faced by patients trying to maintain their drug therapy schedules. With an eye towards personalized medicine, Medisafe strives to build bridges and integrate healthcare services for patients to allow them to better track and manage their health particularly In the age of COVID-19 when patients as well as caregivers are facing new challenges. While being HIPAA and GDPR compliant, Medisafe can also provide valuable information to drug manufacturers and doctors about common barriers to drug adherence.

@medisafeapp #precisionsmedicine #medicationadherence #COVID19

Medisafe.com

Download the the transcript here.

Raj Kannan, CEO, Chiasma is focused on bringing to market oral formulations to patients that face significant challenges with their existing injectable therapies. Targeting those suffering from the rare disease acromegaly, recent approval of MYCAPSSA brings the first and only oral somatostatin analog to a predominantly injectable dominated market. Their proprietary delivery technology solves the problem of getting peptides through the stomach and delivering the medication to the intestine. Chiasma is excited about the potential of MYCAPSSA being a new standard of pharmacological care.

#acromegaly #raredisease #ChronicDisorder #biotechnews

Chiasma.com

Listen to the podcast here

Raj Kannan, CEO, Chiasma is focused on bringing to market oral formulations to patients that face significant challenges with their existing injectable therapies. Targeting those suffering from the rare disease acromegaly, recent approval of MYCAPSSA brings the first and only oral somatostatin analog to a predominantly injectable dominated market. Their proprietary delivery technology solves the problem of getting peptides through the stomach and delivering the medication to the intestine. Chiasma is excited about the potential of MYCAPSSA being a new standard of pharmacological care.

#acromegaly #raredisease #ChronicDisorder #biotechnews

Chiasma.com

Download the transcript here

Marcy Rogers, CEO and Founder, SpineMark is targeting traumatic brain injuries suffered by athletes, kids, seniors and those getting a concussion from an accident or engagement in a military action. Marcy points out this problem is often ignored and currently there are no treatments for concussions except rest. SpineMark is developing a breakthrough drug that is a nanoparticle inhaled through the nose and delivered directly to the brain to start working on reducing inflammation and hopefully prevent secondary concussion syndrome.

#spinemark #concussions #concussion #traumaticbraininjuries

SpineMark.com

Listen to the podcast here.

Marcy Rogers, CEO and Founder, SpineMark is targeting traumatic brain injuries suffered by athletes, kids, seniors and those getting a concussion from an accident or engagement in a military action. Marcy points out this problem is often ignored and currently there are no treatments for concussions except rest. SpineMark is developing a breakthrough drug that is a nanoparticle inhaled through the nose and delivered directly to the brain to start working on reducing inflammation and hopefully prevent secondary concussion syndrome.

#spinemark #concussions #concussion #traumaticbraininjuries

SpineMark.com

Download the transcript here.